BMS and Five Prime push the immune-oncology deal bandwagon along
This article was originally published in Scrip
Executive Summary
Brisk business in the immuno-oncology deal space continues with Bristol-Myers Squibb linking with Five Prime Therapeutics in a discovery, development, and commercialization alliance worth up to $350m for therapies targeted at two undisclosed immune checkpoint pathways.
You may also be interested in...
Deal Watch: Genentech Sees Bicycle As Route To Novel Targeted Cancer Immunotherapies
Genentech pays $30m up front in a collaboration with Bicycle in a deal that could bring the UK biotech roughly $1.7bn in total. Also, deals involving Nimble, Seattle Genetics, Five Prime, Fresenius, Vifor, Yuhan, Imnewrun, Paratek, Almirall, MBD, AzothBio, Norgine, Faes, Aspen Pharmacare, Swixx.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.